Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANNOUNCED POSITIVE DATA FROM THE PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML, REPORTING A CUMULATIVE MMR RATE OF 47% WITH 32% OF PATIENTS ACHIEVING MMR BY 24 WEEKS AND DEMONSTRATING A FAVORABLE SAFETY AND TOLERABILITY PROFILE ACROSS ALL DOSE LEVELS STRONG BALANCE SHEET WITH $ 491 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO THE FIRST HALF OF 2029 BOULDER, COLO. , AUG. 13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE, INCLUDING HIGHLIGHTS OF PIPELINE PROGRESS.

Enliven Therapeutics, Inc.

ELVN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Enliven Therapeutics, Inc.

ELVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ELVN